Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain

Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain

Respiratory syncytial virus (RSV) is the main cause of low respiratory tract infections in infants under one year of age. In the 2023/2024 season, the monoclonal antibody nirsevimab was available to protect children from RSV, and Spain has become one of the first countries worldwide to implement thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Jaime Jesús Pérez Martín, Matilde Zornoza Moreno
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Respiratory syncytial virus
nirsevimab
passive immunization
monoclonal antibody
public health
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2365804
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items